Moleculin BiotechMBRX
13F holders, Q1 2024 (March 31)19holders
$5.91avg. 13F price*
At the end of Q1 2024, 19 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings. The largest holders were Armistice Capital, LLC ($878K), Vanguard Group Inc. ($445K) and Geode Capital Management, LLC ($98K).
- Company
- Moleculin Biotech Inc.
- CUSIP
- 60855D309
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $7K |
| Exits | 0 | $0 |
Ownership 19 holders
| Armistice Capital, LLC | 0.02% | Reduce -30.6% | 148,495 | $878K |
| Vanguard Group Inc. | 0.00% | Add +4.6% | 75,300 | $445K |
| Geode Capital Management, LLC | 0.00% | Add +1.0% | 16,603 | $98K |
| BlackRock Inc. | 0.00% | Reduce -1.0% | 12,473 | $74K |
| Atticus Wealth Management, LLC | 0.01% | No change | 3,334 | $20K |
| NFSG Corp | 0.00% | New | 685 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +29.4% | 621 | $4K |
| Morgan Stanley | 0.00% | Add +0.2% | 423 | $3K |
| FWL Investment Management, LLC | 0.00% | New | 278 | $2K |
| Lanark Financial, Inc. | 0.00% | New | 14 | $1K |
| Sandy Spring Bank | 0.00% | Add +0.1% | 89 | $526 |
| Osaic Holdings, Inc. | 0.00% | Add +0.7% | 65 | $384 |
| CVA Family Office, LLC | 0.00% | Add +2.0% | 34 | $201 |
| Wells Fargo & Company | 0.00% | Add +24.4% | 19 | $112 |
| North Star Investment Management Corp. | 0.00% | Reduce -4.0% | 16 | $95 |
| JPMorgan Chase & Co. | 0.00% | Add +101.9% | 7 | $41 |
| Bank of America Corp. | 0.00% | Reduce -23.9% | 7 | $41 |
| NewEdge Advisors, LLC | 0.00% | Add +650.0% | 1 | $6 |
| Royal Bank of Canada | 0.00% | Reduce -99.3% | 10 | $0 |
"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.